MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

Abstract Background Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement. However, its efficacy is limited by tolerance and acquired resistance, the mechanisms of which are not fully understood. Th...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Subjects:	entrectinib HGF MET NTRK ROS1
Online Access:	https://doi.org/10.1002/cam4.5342